AIM Rule 17 Notification

RNS Number : 5599Y

ReNeuron Group plc

25 February 2013

 



25 February 2013

AIM: RENE

ReNeuron Group plc

("ReNeuron" or "the Company")

AIM Rule 17 Notification

Guildford, UK, 25 February 2013:  Pursuant to Rule 17 of the AIM Rules for Companies (the "AIM Rules"), ReNeuron Group plc (AIM: RENE.L) announces the following change to a director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules.

Paul Harper, a director of the Company, was a director of Angel Biotechnology plc ("Angel") until December 2012. On 11 February 2013, Angel announced that administrators had been appointed with immediate effect.  Accordingly, the Company is required to make this notification.

Enquiries:

ReNeuron                                                                                  [phone]

Michael Hunt, Chief Executive Officer

Dr John Sinden, Chief Scientific Officer 

Buchanan                                                                                    [phone]

Mark Court, Fiona Henson, Sophie Cowles                                                          

Cenkos Securities                                                                      [phone]

Stephen Keys, Adrian Hargrave (NOMAD and Broker)

Andy Roberts (Sales)

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  The Company is also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina such as retinitis pigmentosa.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell^® products for use in academic and commercial research.  The Company's ReNcell^®CX and ReNcell^®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

MSCNKPDQABKKKBB